OPKO Health…today announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck…for the development of MDX-2201, ModeX’s preclinical nanoparticle vaccine candidate targeting EBV.
There is no currently no approved vaccine for EBV.